Sana Biotech Narrows Q3 Loss Amid R&D Cuts, Raises $109M Capital

TL;DR

**SANA is burning less cash and raising more, but the impairment charge and continued losses mean it's still a high-risk bet on future pipeline success.**

AI Summary

Sana Biotechnology, Inc. reported a net loss of $42.15 million for the three months ended September 30, 2025, a significant improvement from the $59.92 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $185.34 million, down from $217.69 million in 2024. Research and development expenses decreased substantially to $30.11 million for the quarter, compared to $53.21 million in Q3 2024, and to $97.06 million for the nine months, down from $170.53 million in the prior year. General and administrative expenses also saw a reduction, falling to $10.29 million for the quarter from $14.05 million. The company recorded a $44.61 million impairment of long-lived assets for the nine months ended September 30, 2025, which was not present in the prior year. Cash, cash equivalents, and marketable securities stood at $153.1 million as of September 30, 2025, down from $127.57 million in cash and cash equivalents and $24.93 million in marketable securities at December 31, 2024. The company raised approximately $80.6 million in net proceeds from an underwritten public offering in August 2025 and an additional $28.6 million from an at-the-market offering during Q3 2025.

Why It Matters

Sana Biotechnology's ability to significantly reduce its net loss and R&D expenses, while simultaneously raising over $109 million in capital, is crucial for its long-term viability in the highly competitive biotech sector. This financial maneuvering suggests a strategic prioritization of its pipeline and a focus on extending its cash runway, which directly impacts investor confidence and the company's ability to fund ongoing clinical trials. For employees, this could signal a more stable operational environment, though the R&D cuts might imply shifts in project focus. Customers and the broader market will be watching to see if these financial adjustments translate into accelerated development of its engineered cell therapies, potentially bringing new treatments to market faster than competitors.

Risk Assessment

Risk Level: high — Sana Biotechnology reported an accumulated deficit of $1.8 billion as of September 30, 2025, and incurred a $44.61 million impairment of long-lived assets during the nine months ended September 30, 2025, indicating significant past losses and asset revaluation. The company explicitly states it expects operating losses to continue for the foreseeable future and is subject to risks including the need for adequate additional funding and potential failure of preclinical or clinical trials.

Analyst Insight

Investors should closely monitor Sana's cash burn rate and the progress of its clinical pipeline, as the company remains in a development stage with no product revenue. The recent capital raises provide a temporary buffer, but sustained profitability hinges on successful product commercialization, making it a speculative investment.

Financial Highlights

net Income

-$42.15M

cash Position

$153.1M

Key Numbers

• $42.15M — Net Loss (Q3 2025) (Reduced from $59.92M in Q3 2024, indicating improved financial performance.)
• $30.11M — Research and Development Expenses (Q3 2025) (Significant decrease from $53.21M in Q3 2024, reflecting strategic cost management.)
• $185.34M — Net Loss (YTD Sep 2025) (Lower than $217.69M for the same period in 2024, showing a trend of narrowing losses.)
• $97.06M — Research and Development Expenses (YTD Sep 2025) (Substantially down from $170.53M in the prior year, indicating a major shift in R&D spending.)
• $44.61M — Impairment of Long-Lived Assets (YTD Sep 2025) (A new charge not present in 2024, impacting total operating expenses.)
• $153.1M — Cash, Cash Equivalents, and Marketable Securities (Sep 30, 2025) (Crucial for funding ongoing operations and R&D, bolstered by recent capital raises.)
• $80.6M — Net Proceeds from Public Offering (Aug 2025) (Significant capital infusion to support liquidity and operations.)
• $28.6M — Net Proceeds from ATM Offering (Q3 2025) (Additional capital raised through an at-the-market facility.)
• $1.8B — Accumulated Deficit (Sep 30, 2025) (Highlights the company's history of operating losses and the need for future profitability.)
• 266,366,120 — Common Shares Outstanding (Oct 29, 2025) (Increased from 223,923,000 at Dec 31, 2024, indicating dilution from recent offerings.)

Key Players & Entities

• Sana Biotechnology, Inc. (company) — registrant
• TD Securities (USA) LLC (company) — sales agent for ATM facility
• TD Cowen (company) — sales agent for ATM facility
• Securities and Exchange Commission (regulator) — filing oversight
• Nasdaq Stock Market LLC (company) — exchange where SANA is registered
• $42.15 million (dollar_amount) — net loss for Q3 2025
• $59.92 million (dollar_amount) — net loss for Q3 2024
• $185.34 million (dollar_amount) — net loss for nine months ended September 30, 2025
• $1.8 billion (dollar_amount) — accumulated deficit as of September 30, 2025
• $44.61 million (dollar_amount) — impairment of long-lived assets for nine months ended September 30, 2025

FAQ

Risk Factors

• Sustained Operating Losses and Need for Future Financing [high — financial]: The company has a history of significant operating losses, as evidenced by an accumulated deficit of $1.8 billion as of September 30, 2025. Continued net losses, such as the $42.15 million loss in Q3 2025, necessitate ongoing access to capital markets to fund operations and development activities.
• Dependence on Research and Development Success [high — operational]: Sana's business model is heavily reliant on the successful development and commercialization of its gene and cell therapies. The substantial R&D expenses, although reduced to $30.11 million in Q3 2025 from $53.21 million in Q3 2024, represent a critical investment. Failure to achieve clinical and regulatory milestones could severely impact future prospects.
• Impairment of Long-Lived Assets [medium — financial]: The company recorded a $44.61 million impairment of long-lived assets for the nine months ended September 30, 2025. This charge indicates potential issues with the valuation or utility of certain assets, which could recur and impact profitability.
• Dilution from Equity Offerings [medium — financial]: The company has actively raised capital through public and at-the-market offerings, resulting in an increase in common shares outstanding to 266,366,120 as of October 29, 2025, from 223,923,000 at December 31, 2024. While these offerings bolster liquidity, they also dilute existing shareholders' ownership.
• Complex and Evolving Regulatory Landscape [high — regulatory]: Developing and obtaining approval for novel gene and cell therapies involves navigating a complex and rapidly evolving regulatory environment. Delays or rejections from regulatory bodies like the FDA could significantly hinder product development and market entry.

Industry Context

Sana Biotechnology operates in the highly competitive and rapidly evolving biotechnology sector, specifically focusing on gene and cell therapies. This field is characterized by significant R&D investment, long development cycles, and a complex regulatory pathway. Success hinges on scientific innovation and the ability to navigate clinical trials and regulatory approvals.

Regulatory Implications

The development of gene and cell therapies is subject to stringent oversight by regulatory bodies such as the FDA. Any changes in regulatory requirements or delays in approval processes can significantly impact the timeline and cost of bringing products to market, posing a substantial risk to the company.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-08-01: Underwritten Public Offering — Raised approximately $80.6 million in net proceeds, significantly bolstering the company's cash reserves and providing runway for operations and R&D.
• 2025-09-30: End of Q3 2025 — Reported a net loss of $42.15 million and ended the period with $153.1 million in cash, cash equivalents, and marketable securities, reflecting improved cost management but continued operational burn.
• 2025-10-29: Common Shares Outstanding Update — Reported 266,366,120 common shares outstanding, indicating dilution from recent capital raises which is a key consideration for investors.

Glossary

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total amount of money a company has lost over its lifetime. (Indicates Sana's history of operating losses, currently at $1.8 billion as of September 30, 2025, highlighting its reliance on external funding.)

Impairment of Long-Lived Assets

A charge taken when the carrying amount of a long-lived asset (such as property, plant, or equipment) exceeds its fair value, indicating a permanent reduction in its economic value. (Sana recorded a $44.61 million impairment in the first nine months of 2025, suggesting a write-down of asset value that impacts profitability.)

At-the-Market (ATM) Offering

A type of public offering where a company sells its shares directly into the open market over a period of time, typically through an intermediary, at prevailing market prices. (Sana raised $28.6 million through an ATM offering in Q3 2025, demonstrating a flexible approach to capital raising to supplement its cash position.)

Gene and Cell Therapies

Advanced therapeutic approaches that involve modifying or replacing genes or cells to treat diseases. (These are Sana's core focus areas, representing a high-risk, high-reward segment of the biotechnology industry.)

Year-Over-Year Comparison

Compared to the prior year, Sana Biotechnology has demonstrated improved financial performance with a reduced net loss of $42.15 million in Q3 2025 versus $59.92 million in Q3 2024, and a narrowed year-to-date loss of $185.34 million compared to $217.69 million. A significant reduction in R&D expenses, from $53.21 million in Q3 2024 to $30.11 million in Q3 2025, highlights a strategic shift in spending. However, a new $44.61 million impairment of long-lived assets for the nine months of 2025 was recorded, which was not present in the prior year, impacting overall financial results.

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SANA The Nasdaq

Filing Documents

• sana-20250930.htm (10-Q) — 3296KB
• sana-ex31_1.htm (EX-31.1) — 18KB
• sana-ex32_1.htm (EX-32.1) — 10KB
• 0001193125-25-269569.txt ( ) — 11226KB
• sana-20250930.xsd (EX-101.SCH) — 1339KB
• sana-20250930_htm.xml (XML) — 2036KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Comprehensive Loss 7 Condensed Consolidated Statements of Stockholders' Equity 8 Condensed Consolidated Statements of Cash Flows 10 Notes to Condensed Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 35 Item 4.

Controls and Procedures

Controls and Procedures 36 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 37 Item 1A.

Risk Factors

Risk Factors 37 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 114 Item 3. Defaults Upon Senior Securities 114 Item 4. Mine Safety Disclosures 114 Item 5. Other Information 114 Item 6. Exhibits 115

Signatures

Signatures 116 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (Quarterly Report) contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report could be deemed forward-looking statements, including those statements highlighted below. In some cases, you can identify these statements by forward-looking words such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," "would," or "will," the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, include, but are not limited to, statements about: our expectations regarding the potential market size and size of the potential patient populations for our product candidates and any future product candidates, if approved for commercial use; our clinical and regulatory development plans; our expectations with regard to our preclinical studies, clinical trials, regulatory submissions, and research and development programs, including the impact, timing, and availability of data from such studies and trials; the timing of commencement and advancement of future preclinical studies, clinical trials, and research and development programs; our ability to acquire, discover, and develop product candidates and timely advance them into and through clinical data readouts and successful completion of clinical trials; our expectations regarding the potential safety, efficacy, or clinical utility of our product candidates; our expectations regarding our business strategy following the implementation of portfolio prioritizations and adjustments in our business strategy, including with respect to our research and development focus on our remaining programs; our intentions with respect to and our ability to establish

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

Financ ial Statements

Item 1. Financ ial Statements Sana Biotechnology, Inc. Condensed Consolida ted Balance Sheets (in thousands, except per share amounts) September 30, 2025 December 31, 2024 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 103,357 $ 127,566 Marketable securities 49,697 24,931 Restricted cash 4,195 3,832 Prepaid expenses and other current assets 4,510 4,479 Total current assets 161,759 160,808 Property and equipment, net 29,931 77,308 Operating lease right-of-use assets 40,704 57,961 Intangible asset 59,195 59,195 Goodwill 140,627 140,627 Other non-current assets 3,216 5,121 TOTAL ASSETS $ 435,432 $ 501,020 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 1,858 $ 5,210 Accrued compensation 11,296 14,449 Accrued expenses and other current liabilities 7,991 13,240 Operating lease liabilities 14,368 12,534 Total current liabilities 35,513 45,433 Operating lease liabilities, net of current portion 67,868 81,663 Contingent consideration 115,141 108,968 Success payment liabilities 13,726 4,556 Other non-current liabilities 7,876 9,896 Total liabilities 240,124 250,516 Commitments and contingencies (Note 10) Stockholders' equity: Preferred stock, $ 0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of September 30, 2025 and December 31, 2024 - - Common stock, $ 0.0001 par value; 750,000 shares authorized; 262,264 and 223,923 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 26 22 Additional paid-in capital 1,985,452 1,855,318 Accumulated other comprehensive income 21 14 Accumulated deficit ( 1,790,191 ) ( 1,604,850 ) Total stockholders' equity 195,308 250,504 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 435,432 $ 501,020 See accompanying notes. 5 San